PKC inhibitor J-4 and PLK1/2 inhibitor onvansertib are in preclinical and clinical trials, respectively, and by inhibiting these molecules, endogenous FBXW7 expression may be restored and promote the turnover of breast cancer-associated oncogenic proteins [131, 132] (Fig. 6B). This evidence concerns the gene FBXW7 and breast cancer.